Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques - Wikidata - wikimedia - TriplyDB

Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques

Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques

http://www.wikidata.org/entity/Q36593663

about

Animal and human mucosal tissue models to study HIV biomedical interventions: can we predict success?Maraviroc: a review of its use in HIV infection and beyond Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma.Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.Electrospun solid dispersions of Maraviroc for rapid intravaginal preexposure prophylaxis of HIV Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application.Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.C5A Protects Macaques from Vaginal Simian-Human Immunodeficiency Virus Challenge.Pharmacokinetic and Pharmacodynamic Evaluation following Vaginal Application of IQB3002, a Dual-Chamber Microbicide Gel Containing the Nonnucleoside Reverse Transcriptase Inhibitor IQP-0528 in Rhesus Macaques.Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.Animal models for microbicide safety and efficacy testing.Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay.Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues CD4-mimetic sulfopeptide conjugates display sub-nanomolar anti-HIV-1 activity and protect macaques against a SHIV162P3 vaginal challenge.Current strategies for sustaining drug release from electrospun nanofibers.Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application.Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides.Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.Beyond HIV microbicides: multipurpose prevention technology products.The therapeutic potential of vaginal drug delivery in the treatment of cervical cancer.Coaxially electrospun fiber-based microbicides facilitate broadly tunable release of maraviroc Disulfiram-loaded immediate and extended release vaginal tablets for the localised treatment of cervical cancer.Vaginal drug delivery for the localised treatment of cervical cancer.A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.

P2860

Q26777022-6E9CA8F8-AB4F-449B-9717-DBF1A54DD59D Q26778504-3EA5A394-33BF-4E60-9085-8ECC87BAA47B Q30366071-C6F08A32-9B30-4541-A009-C4AF01351F96 Q33643626-9FD24B11-C97B-49D9-8D4B-73F51A590600 Q33821090-951D3863-EA8C-4594-BE13-9A970BC98E00 Q33888718-A9EE7DCD-F399-4147-9173-952D9AECEF34 Q34057568-5C100938-39D2-4390-9A5D-7CB3D7280C15 Q34058160-C3182BCE-F7C2-4B7E-9692-6AF85E5D8433 Q34085477-BBD3291C-2600-423A-8915-92CA841132BA Q35794988-C9FEA717-11BC-4903-A677-D435EEFBC348 Q35947035-DE67ACC5-4ADC-49D5-80E6-E27DDFCC9BF8 Q36143276-6DFC7811-34FC-4C2C-A48B-83B39FDB7A61 Q36306935-76F25D4B-37AF-4A50-9B54-D95C30F38459 Q36438963-56598172-C255-4B79-97DA-CC748F67BC2E Q36644657-158C5C8C-3925-46EB-8B4A-BE7562DD4382 Q36756170-DFBCFC33-DD98-45FB-A07B-4E2DBCF2F539 Q36785795-36C74FCC-2B6D-4CBE-9244-A35B52E64B1E Q36911645-97890B1E-EDFC-4CED-AE06-110AE451CD92 Q36989915-00309BFB-9285-42BE-94CF-1E5A913EDB3E Q37042100-AEFED8AF-7208-4494-9458-4E4A9515FB31 Q37123335-DA72852B-47B5-40C9-BA03-C7F6A7584309 Q37323948-978346EA-6E79-4861-84C5-7E4EC6E9558B Q37585816-62520089-0A3D-49A5-BF7A-48DB00FB2753 Q37688254-0298E52A-7EB2-4F0A-9714-C5091BFADC13 Q37707803-5D01DDFC-00DC-4F45-AE32-6032A2312754 Q38196457-B75816E9-AF98-495F-BEBE-E7A1A1B0480F Q38261814-AC6A0E8E-6D99-4B99-AEEE-F1907A1BC17D Q38498021-F1177767-2FE2-416D-8D0F-E64533ADE806 Q38781199-ED59B5BE-A62C-4DBE-9CBA-568B04DC3861 Q38930082-B87511CF-C8CC-47C8-9568-AF21CF434CB6 Q39361267-4BDC3744-BA24-4A28-8582-B54617FF99DB Q39905748-68FB4448-9098-4430-BA01-CDF2F6314609

P2860

Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques

http://www.wikidata.org/entity/Q36593663

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Pharmacokinetics and efficacy ...... raviroc gel in rhesus macaques

@ast

Pharmacokinetics and efficacy ...... raviroc gel in rhesus macaques

@en

type

label

Pharmacokinetics and efficacy ...... raviroc gel in rhesus macaques

@ast

Pharmacokinetics and efficacy ...... raviroc gel in rhesus macaques

@en

prefLabel

Pharmacokinetics and efficacy ...... raviroc gel in rhesus macaques

@ast

Pharmacokinetics and efficacy ...... raviroc gel in rhesus macaques

@en

P1433

Q36593663-396C73D8-DC10-49D2-852D-CFDDC1110863

P1476

Q36593663-AC90462A-2499-4F25-BE8D-56B22B2C2D0F

P2093

Q36593663-14BDEF1E-D8E7-4328-909A-00109C815E88

Q36593663-30F26EA7-6078-4A6B-9FB3-4AD03EDAD8C8

Q36593663-522B6A24-4F00-4CDE-8F4D-7B7ABEAB592B

Q36593663-60F7ACBD-7086-4C04-9632-EBAC03B724D4

Q36593663-99C4747F-9859-4648-B8E6-00D2EDF95056

Q36593663-C2BF581B-2FCA-4FF7-BBBB-7494DF2B8222

Q36593663-F1F5E4B6-162C-44E2-8EBC-3C6BAD211400

P2860

Q36593663-0B2AAA27-B4FA-4A2F-8DE1-5CDB36E7BE81

Q36593663-0D8B07FA-3349-41F0-BE13-B604A5B2B078

Q36593663-0FB8B526-DAAE-4DE5-BBE3-386B153D5847

Q36593663-192EAFB6-AB74-46AB-B7FA-442B19CFC76A

Q36593663-22E393BF-BED0-4212-A7A4-5F678963A05E

Q36593663-2AFC4B86-73AC-495A-8642-4B45A3DA2AC8

Q36593663-2E2FCB8A-8491-4DB4-BF1C-1DDFC90A77EC

Q36593663-3A73D0B4-AB74-4715-8601-9D118F1F0E54

Q36593663-3A7EB84D-6E14-4F84-9AA4-3D510EC2E42F

Q36593663-4D0AB129-8236-4E92-AF1D-98865D2E94BD

P304

Q36593663-B6AFC558-9694-414A-BB5D-C02EB3F47CB6

P31

Q36593663-569CA1D9-3AF5-4ED3-B3D2-6D9147902976

P356

Q36593663-B482AFF3-80A4-43A6-85A2-6F6F15123968

P407

Q36593663-39F8E9AB-0CEC-4471-B88B-F58B24381F61

P433

Q36593663-51268ED5-18B8-4EB2-BDD0-CF58A0FC8983

P478

Q36593663-A6B65B58-552C-4C04-B280-60E30BA5C948

P577

Q36593663-60F69DC9-00B6-4A55-90F9-417E4D22B748

P5875

Q36593663-62871338-2B94-4A53-8A28-341ACD56DF70

P698

Q36593663-282EDC2A-8A59-4F4C-8B43-866CAE2CA222

P932

Q36593663-9E1DE9BE-C1AE-42F1-9206-AD93E271700E

P356

P1433

Journal of Antimicrobial Chemotherapy

P1476

Pharmacokinetics and efficacy ...... raviroc gel in rhesus macaques

@en

P2093

Claire J Forbes

http://www.w3.org/2001/XMLSchema#string

John P Moore

http://www.w3.org/2001/XMLSchema#string

Laurie Goldman

http://www.w3.org/2001/XMLSchema#string

Leslie Geer

http://www.w3.org/2001/XMLSchema#string

Per Johan Klasse

http://www.w3.org/2001/XMLSchema#string

R Karl Malcolm

http://www.w3.org/2001/XMLSchema#string

Ronald S Veazey

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

Microbicides: topical prevention against HIV

A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice

SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses

A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel

Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.

Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.

Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings

Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques

P304

678-683

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKS422

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232741608

http://www.w3.org/2001/XMLSchema#string

P698

23111849

http://www.w3.org/2001/XMLSchema#string

P932

3566668

http://www.w3.org/2001/XMLSchema#string